An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms Meeting Abstract
| Authors: | Rampal, R.; Ramanathan, S.; Papayannidis, C.; von Bubnoff, N.; Díaz, M. D. T.; Vidriales, M. B.; Burguera, A. D. L. F.; Masarova, L.; Al-Ali, H. K.; Lavie, D.; Niyongere, S.; Chan, T.; McGreivy, J. S.; Rothbaum, W. P.; Mims, A. S.; Cluzeau, T. |
| Abstract Title: | An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305061 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS7063 |
| Notes: | Meeting Abstract: TPS7063 -- Meeting also held virtually -- Source: Wos |
